Triazolam and Hypopituitarism - a phase IV clinical study of FDA data

Summary:

Hypopituitarism is reported as a side effect among people who take Triazolam (triazolam), especially for people who are male, 60+ old, also take Opdivo, and have Lung cancer - non-small cell.

The phase IV clinical study analyzes which people have Hypopituitarism when taking Triazolam. It is created by eHealthMe based on reports of 5,701 people who have side effects when taking Triazolam from the FDA, and is updated regularly.

What is Triazolam?

Triazolam has active ingredients of triazolam. It is often used in insomnia. eHealthMe is studying from 5,838 Triazolam users. Check the latest studies of Triazolam.

What is Hypopituitarism?

Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults) is found to be associated with 202 drugs and 451 conditions by eHealthMe. Check the latest studies of Hypopituitarism.

On Aug, 09, 2026

5,701 people reported to have side effects when taking Triazolam.
Among them, 11 people (0.19%) have Hypopituitarism.

Among these 11 people:

What is the gender of people who have Hypopituitarism when taking Triazolam? *

female: 27.27 %
male: 72.73 %

What is the age of people who have Hypopituitarism when taking Triazolam? *

What are other drugs people take besides Triazolam? *

What are other side effects people have besides Hypopituitarism? *

Dermatomyositis (inflammation of the skin and underlying muscle tissue, typically occurring as an autoimmune condition or associated with internal cancer): 4 people, 36.36%
Weakness: 3 people, 27.27%
Myositis (inflammation of the muscles): 3 people, 27.27%
Amyotrophy (muscular wasting or atrophy): 3 people, 27.27%
Blood Creatine Phosphokinase Increased: 3 people, 27.27%
Hypophagia (reduced food intake): 3 people, 27.27%
Hypophysitis (inflammation of the pituitary gland): 3 people, 27.27%
Itching: 3 people, 27.27%
Muscle Aches (muscle pain): 3 people, 27.27%
Myopathy (a muscular disease in which the muscle fibres do not function): 3 people, 27.27%

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 6 people, 54.55%
High Blood Pressure: 3 people, 27.27%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 2 people, 18.18%
Malignant Melanoma (skin cancer rises from melancytes): 2 people, 18.18%
Ureteric Cancer: 1 person, 9.09%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 9.09%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Triazolam and have Hypopituitarism?

- Check whether Hypopituitarism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Triazolam:

Triazolam (5,838 reports)

Hypopituitarism treatments and more:

Hypopituitarism (11,449 reports)

Browse all side effects of Triazolam:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypopituitarism:

Hypopituitarism (202 drugs)

Browse all the conditions that are associated with Hypopituitarism:

Hypopituitarism (451 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on triazolam (the active ingredients of Triazolam) and Triazolam (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.